
ESTA Stock Forecast & Price Target
ESTA Analyst Ratings
Bulls say
Establishment Labs Holdings Inc. has demonstrated a significant improvement in its financial performance, with an EBITDA margin that increased 1,960 basis points year-over-year and a gross margin of 70.1%, surpassing consensus expectations. The company's strategic launch of the Motiva implants has revitalized the breast aesthetics market, contributing to approximately 15% year-over-year growth in procedure volumes among practices offering these products. Additionally, the positive outlook is further supported by projected cash reserves of $75.5 million by the end of 2026, up from $71 million in the third quarter of 2025, indicating robust financial health and growth potential.
Bears say
Establishment Labs Holdings Inc. faces significant challenges, as revenue growth is projected to decrease to below 20% due to weaker-than-expected sales in the U.S. market, compounded by slow progress towards profitability. Additionally, international growth has markedly slowed, with estimates suggesting approximately 2% growth in 2023, a 2% decline in 2024, and a return to 2% growth in 2025. The company also confronts multiple risks, including disappointing sales performance, potential economic downturns affecting international sales, and concerns regarding real-world complication rates, which could further impact its financial stability.
This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ESTA Analyst Forecast & Price Prediction
Start investing in ESTA
Order type
Buy in
Order amount
Est. shares
0 shares